{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:56Z","timestamp":1791920876365,"version":"4.3.4"},"reference-count":79,"publisher":"American Medical Association (AMA)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2019,6,11]]},"DOI":"10.1001\/jama.2019.2591","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T11:58:13Z","timestamp":1560254293000},"page":"2214","source":"Crossref","is-referenced-by-count":246,"title":["Preexposure Prophylaxis for the Prevention of HIV Infection"],"prefix":"10.1001","volume":"321","author":[{"given":"Roger","family":"Chou","sequence":"first","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland"},{"name":"Division of General Internal Medicine and Geriatrics, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Evans","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Geriatrics, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hoverman","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University\u2013Portland State University School of Public Health, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Sun","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University\u2013Portland State University School of Public Health, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Dana","sequence":"additional","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bougatsos","sequence":"additional","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Grusing","sequence":"additional","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Geriatrics, Oregon Health & Science University, Portland"},{"name":"Oregon Health & Science University\u2013Portland State University School of Public Health, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"jus190003r3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jclinepi.2008.06.007","article-title":"AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program.","volume":"63","author":"Chou","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"12, pt 2","key":"jus190003r4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.7326\/0003-4819-142-12_Part_2-200506211-00009","article-title":"Challenges in systematic reviews that assess treatment harms.","volume":"142","author":"Chou","year":"2005","journal-title":"Ann Intern Med"},{"issue":"7414","key":"jus190003r5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"jus190003r6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: a time for change.","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"issue":"12","key":"jus190003r8","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS"},{"key":"jus190003r10","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"jus190003r11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10461-014-0859-z","article-title":"Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials.","volume":"19","author":"Agot","year":"2015","journal-title":"AIDS Behav"},{"issue":"5","key":"jus190003r12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"jus190003r13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/QAD.0000000000000102","article-title":"CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.","volume":"28","author":"Chirwa","year":"2014","journal-title":"AIDS"},{"issue":"9883","key":"jus190003r14","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"jus190003r15","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1016\/S2352-3018(15)00206-4","article-title":"HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.","volume":"2","author":"Deutsch","year":"2015","journal-title":"Lancet HIV"},{"issue":"3","key":"jus190003r16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.","volume":"66","author":"Donnell","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"27","key":"jus190003r17","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"jus190003r18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/QAI.0b013e31828ece33","article-title":"Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.","volume":"64","author":"Grohskopf","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"jus190003r19","doi-asserted-by":"publisher","first-page":"e1001511","DOI":"10.1371\/journal.pmed.1001511","article-title":"Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.","volume":"10","author":"Haberer","year":"2013","journal-title":"PLoS Med"},{"issue":"18","key":"jus190003r20","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1097\/QAD.0000000000000493","article-title":"Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.","volume":"28","author":"Heffron","year":"2014","journal-title":"AIDS"},{"issue":"9","key":"jus190003r21","doi-asserted-by":"publisher","first-page":"e74314","DOI":"10.1371\/journal.pone.0074314","article-title":"Safety, adherence and acceptability of intermittent tenofovir\/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.","volume":"8","author":"Kibengo","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"jus190003r22","first-page":"1211","article-title":"Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.","volume":"211","author":"Lehman","year":"2015","journal-title":"J Infect Dis"},{"issue":"8","key":"jus190003r23","doi-asserted-by":"publisher","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","article-title":"Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"jus190003r24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/QAI.0000000000000351","article-title":"Patterns and correlates of PrEP drug detection among MSM and transgender women in the global iPrEx study.","volume":"67","author":"Liu","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"jus190003r25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/2050-6511-15-77","article-title":"Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.","volume":"15","author":"Mandala","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"jus190003r26","doi-asserted-by":"publisher","first-page":"e91513","DOI":"10.1371\/journal.pone.0091513","article-title":"Daily oral emtricitabine\/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.","volume":"9","author":"Marcus","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"jus190003r27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women.","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"jus190003r28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/cid\/ciu355","article-title":"Renal function of participants in the Bangkok Tenofovir Study\u2014Thailand, 2005-2012.","volume":"59","author":"Martin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"7","key":"jus190003r29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/QAD.0000000000000613","article-title":"The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.","volume":"29","author":"Martin","year":"2015","journal-title":"AIDS"},{"issue":"1","key":"jus190003r30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/QAI.0000000000000246","article-title":"High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.","volume":"67","author":"Matthews","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10013","key":"jus190003r31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"jus190003r32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/QAI.0000000000000858","article-title":"Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis.","volume":"71","author":"Mirembe","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"23","key":"jus190003r33","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"jus190003r34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jama.2014.8735","article-title":"Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.","volume":"312","author":"Mugo","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"jus190003r35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamainternmed.2014.6786","article-title":"Changes in glomerular kidney function among HIV-1\u2013uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.","volume":"175","author":"Mugwanya","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"4","key":"jus190003r36","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/cid\/civ324","article-title":"Effects of emtricitabine\/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial.","volume":"61","author":"Mulligan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"13","key":"jus190003r37","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1097\/QAD.0b013e3283629037","article-title":"Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.","volume":"27","author":"Murnane","year":"2013","journal-title":"AIDS"},{"issue":"10","key":"jus190003r38","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/aje\/kwv202","article-title":"Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.","volume":"182","author":"Murnane","year":"2015","journal-title":"Am J Epidemiol"},{"issue":"4","key":"jus190003r39","doi-asserted-by":"publisher","first-page":"e33103","DOI":"10.1371\/journal.pone.0033103","article-title":"Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.","volume":"7","author":"Mutua","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"jus190003r40","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1371\/journal.pctr.0020027","article-title":"Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial.","volume":"2","author":"Peterson","year":"2007","journal-title":"PLoS Clin Trials"},{"issue":"6","key":"jus190003r41","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/QAD.0000000000000156","article-title":"Changes in renal function associated with oral emtricitabine\/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.","volume":"28","author":"Solomon","year":"2014","journal-title":"AIDS"},{"issue":"5","key":"jus190003r42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"jus190003r43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women.","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"jus190003r44","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/QAD.0000000000000313","article-title":"Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.","volume":"28","author":"Were","year":"2014","journal-title":"AIDS"},{"issue":"2","key":"jus190003r45","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/S2352-3018(17)30156-X","article-title":"Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067\/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.","volume":"5","author":"Bekker","year":"2018","journal-title":"Lancet HIV"},{"issue":"11","key":"jus190003r46","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/cid\/cix1086","article-title":"Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: the Human Immunodeficiency Virus Prevention Trials Network 067\/ADAPT study.","volume":"66","author":"Grant","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"jus190003r47","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/QAI.0b013e3182801081","article-title":"The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men.","volume":"62","author":"Hosek","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"jus190003r48","doi-asserted-by":"publisher","first-page":"20903","DOI":"10.7448\/IAS.19.1.20903","article-title":"Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities.","volume":"19","author":"Chan","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"jus190003r49","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamapediatrics.2017.2007","article-title":"Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States.","volume":"171","author":"Hosek","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"1","key":"jus190003r50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/QAI.0000000000001179","article-title":"An HIV preexposure prophylaxis demonstration project and safety study for young MSM.","volume":"74","author":"Hosek","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"jus190003r51","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"jus190003r52","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/QAI.0000000000001538","article-title":"Plasma tenofovir levels to support adherence to TDF\/FTC preexposure prophylaxis for HIV prevention in MSM in Los Angeles, California.","volume":"76","author":"Landovitz","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"jus190003r53","doi-asserted-by":"publisher","first-page":"e0157742","DOI":"10.1371\/journal.pone.0157742","article-title":"Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting.","volume":"11","author":"Montgomery","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"jus190003r54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services.","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"3","key":"jus190003r55","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/QAI.0000000000001598","article-title":"Medication adherence in a nationwide cohort of veterans initiating pre-exposure prophylaxis (PrEP) to prevent HIV infection.","volume":"77","author":"van Epps","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"jus190003r56","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/OLQ.0000000000000535","article-title":"Are Centers for Disease Control and Prevention guidelines for preexposure prophylaxis specific enough? formulation of a personalized HIV risk score for pre-exposure prophylaxis initiation.","volume":"44","author":"Beymer","year":"2017","journal-title":"Sex Transm Dis"},{"issue":"3","key":"jus190003r57","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/cid\/civ335","article-title":"Development and validation of the San Diego Early Test Score to predict acute and early HIV infection risk in men who have sex with men.","volume":"61","author":"Hoenigl","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"9","key":"jus190003r58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/OLQ.0b013e3181a9cc41","article-title":"Prediction of HIV acquisition among men who have sex with men.","volume":"36","author":"Menza","year":"2009","journal-title":"Sex Transm Dis"},{"issue":"4","key":"jus190003r59","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/QAI.0b013e318256b2f6","article-title":"Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States.","volume":"60","author":"Smith","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"jus190003r60","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/ADM.0000000000000123","article-title":"A brief screening tool to assess the risk of contracting HIV infection among active injection drug users.","volume":"9","author":"Smith","year":"2015","journal-title":"J Addict Med"},{"issue":"3","key":"jus190003r61","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/QAD.0000000000001710","article-title":"Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young black MSM in Chicago.","volume":"32","author":"Lancki","year":"2018","journal-title":"AIDS"},{"issue":"5","key":"jus190003r62","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/OLQ.0000000000000596","article-title":"Assessing the performance of 3 human immunodeficiency virus incidence risk scores in a cohort of black and white men who have sex with men in the South.","volume":"44","author":"Jones","year":"2017","journal-title":"Sex Transm Dis"},{"issue":"3","key":"jus190003r63","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/QAI.0000000000000974","article-title":"An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women.","volume":"72","author":"Balkus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"jus190003r64","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/QAI.0b013e31827e622d","article-title":"An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention.","volume":"62","author":"Kahle","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"jus190003r65","first-page":"751","article-title":"A risk assessment tool for identifying pregnant and postpartum women who may benefit from preexposure prophylaxis.","volume":"64","author":"Pintye","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jus190003r66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/M13-2471","article-title":"Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.","volume":"161","author":"Celum","year":"2014","journal-title":"Ann Intern Med"},{"issue":"151","key":"jus190003r67","doi-asserted-by":"publisher","first-page":"151ra125","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.","volume":"4","author":"Anderson","year":"2012","journal-title":"Sci Transl Med"},{"issue":"1","key":"jus190003r68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine.","volume":"214","author":"Cottrell","year":"2016","journal-title":"J Infect Dis"},{"issue":"7","key":"jus190003r69","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/infdis\/jiw312","article-title":"Chemoprophylaxis with oral emtricitabine and tenofovir alafenamide combination protects macaques from rectal simian\/human immunodeficiency virus infection.","volume":"214","author":"Massud","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"jus190003r70","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/cid\/ciy182","article-title":"Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis.","volume":"67","author":"Traeger","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"7","key":"jus190003r71","first-page":"CD007189","article-title":"Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.","volume":"7","author":"Okwundu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"jus190003r72","doi-asserted-by":"publisher","first-page":"e87674","DOI":"10.1371\/journal.pone.0087674","article-title":"Pre-exposure prophylaxis for the prevention of HIV infection in high-risk populations: a meta-analysis of randomized controlled trials.","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"jus190003r75","doi-asserted-by":"publisher","first-page":"384","DOI":"10.7326\/M17-0520","article-title":"Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: a phase 2 randomized trial.","volume":"167","author":"Gulick","year":"2017","journal-title":"Ann Intern Med"},{"issue":"2","key":"jus190003r76","first-page":"238","article-title":"Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (HPTN 069\/ACTG A5305).","volume":"215","author":"Gulick","year":"2017","journal-title":"J Infect Dis"},{"key":"jus190003r9","volume-title":"Pre-Exposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review for the U.S. Preventive Services Task Force: Evidence Synthesis No. 178","author":"Chou","year":"2018"},{"key":"jus190003r73","volume-title":"Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV\u2014United States, 2016","author":"Centers for Disease Control and Prevention","year":"2016"},{"key":"jus190003r1","unstructured":"US Preventive Services Task Force (USPSTF). USPSTF Procedure Manual. USPSTF website. https:\/\/www.uspreventiveservicestaskforce.org\/Home\/GetFile\/6\/7\/procedure-manual_2016\/pdf. Published 2016. Accessed December 8, 2017."},{"key":"jus190003r2","unstructured":"US Public Health Service, Centers for Disease Control and Prevention (CDC). Preexposure Prophylaxis for the Prevention of HIV infection in the United States\u20142017 Update: a Clinical Practice Guideline. CDC website. https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2017.pdf. Published 2017. Accessed August 9, 2018."},{"key":"jus190003r7","unstructured":"Center for Drug Evaluation and Research (CDER). Clinical review: emtricitabine\/tenofovir disoproxil fumarate. US Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/021752Orig1s030MedR.pdf. Published 2011. Accessed February 2, 2018."},{"key":"jus190003r74","unstructured":"Gilead Sciences. Safety and efficacy of emtricitabine and tenofovir alafenamide (F\/TAF) fixed-dose combination once daily for pre-exposure prophylaxis in men and transgender women who have sex with men and are at risk of HIV-1 infection (DISCOVER) [NCT02842086]. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02842086?term=NCT02842086&rank=1. 2016. Accessed December 8, 2017."},{"key":"jus190003r77","unstructured":"National Institute of Allergy and Infectious Diseases. Safety and efficacy study of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC), for pre-exposure prophylaxis in HIV-uninfected cisgender men and transgender women who have sex with men [NCT02720094]. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02720094. 2016. Accessed December 11, 2017."},{"key":"jus190003r78","unstructured":"National Institute of Allergy and Infectious Diseases. Evaluating the safety and efficacy of long-acting injectable cabotegravir compared to daily oral TDF\/FTC for pre-exposure prophylaxis in HIV-uninfected women [NCT03164564]. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03164564. 2017. Accessed February 2, 2018."},{"key":"jus190003r79","unstructured":"PATH. Phase II safety and acceptability of an investigational injectable product, TMC278LA, for pre-exposure prophylaxis (TMC278LA) [NCT02165202]. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02165202. 2017. Accessed December 8, 2017."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jama\/article-pdf\/321\/22\/2214\/17644145\/jama_chou_2019_us_190003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T07:14:06Z","timestamp":1663658046000},"score":1,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2019.2591"}},"subtitle":["Evidence Report and Systematic Review for the US Preventive Services Task Force"],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":79,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,6,11]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2019.2591","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,11]]}}}